FOR IMMEDIATE RELEASE
Thursday, January 11, 200
Slaughter Calls for Federal Investment in Stem Cell Research House Passes Bi-Partisan Stem Cell Bill 253 - 174
Washington, DC - Rep. Louise M. Slaughter (D-NY-28), Chairwoman of the House Rules Committee, today addressed the House of Representatives on the need for federal investment in embryonic stem cell research.
" Embryonic stem cell research is one of the most promising fields in modern medical research ," said Rep. Slaughter. " Refusing to federally fund research toward the cures it could bring would be unconscionable. The American people support it, the Congress supports it, and it is the right thing to do."
"I believe people in wheelchairs will one day walk again," Rep. Slaughter said. "I believe that we can bring about an entirely new form of healthcare in America - one defined by shorter hospital stays, fewer invasive procedures, and increasing benefits to

both our patients and our bottom line."
Rep. Slaughter, who holds a master's degree in Microbiology, has been one of the leading voices in Congress in support of federal funding for embryonic stem cell research. Citing the overwhelming body of scientific research already done in the field, she called upon her fellow Representatives to support the legislation, which passed in the House today by a vote of 253 to 174. The bill now moves to the Senate where it is also expected to pass.
Embryonic stem cell research is one of the top priorities of the new Democratic Congress, featured prominently in the "First 100 Hours" legislative agenda. Last year, President Bush used the first and only veto of his Presidency to strike down an identical stem cell bill that passed with broad bi-partisan support in both chambers of Congress. Now, with a majority in the House and Senate, Democrats have brought the issue into the forefront of public debate at a time when over seventy percent of the public supports embryonic stem cell research.
The complete text of Representative Slaughter's remarks, as prepared, are included below:
M. Speaker,

January 11, 2007 - Slaughter Calls for Federal Investment in Stem Cell Research

January 11, 2007 - Slaughter Calls for Federal Investment in Stem Cell Research

are taking great strides forward. In the end, enforcing restrictive federal research policies will only ensure that the United States will continue to lose many of our best and brightest scientists in this field to other countries.
M. Speaker, many of history's greatest medical killers now have cures because of scientific research. Tens of millions of lives have been saved as a result. Today, we have the potential to save millions more, and to leave other deadly diseases behind us.
I believe people in wheelchairs will one day walk again. I believe that we can bring about an entirely new form of healthcare in America - one defined by shorter hospital stays, fewer invasive procedures, and increasing benefits to both our patients and our bottom line.
The bill before us today presents an ethical solution to research that could potentially benefit almost every American. It gives our country hope - hope that one day we won't have to watch our mothers die of breast cancer, our grandparents suffer from Alzheimer's, and our own children endure Type I diabetes.
If we fail to fund embryonic stem cell research, I do not believe that we will be able to look our children and grandchildren, our mothers or fathers, or our grandparents in the eye and tell them we did everything we could to help them live a better, healthier, longer, happier life.

I urge my colleagues who have second thoughts about this bill to step back and think of a loved one who could possibly benefit from this research. Your vote today should be clear.

FURTHER BACKGROUND:

- Last year, President Bush vetoed H.R. 810, a bipartisan bill that would have allowed federal funding of embryonic stem cell research. The bill passed the House by a 238-194 vote and the Senate by a 63-37 vote.
- Over 100 million Americans suffer from cancer, Parkinson's, Alzheimer's, diabetes, spinal cord injuries and other debilitating diseases and disorders for which embryonic stem cell research holds great promise in finding new and better treatments and cures.
- Expanding stem cell research has strong bipartisan support in Congress, and is supported by over 72 percent of Americans. [Opinion Research Corporation]
- The DeGette-Castle bill increases the number of embryonic stem cell lines eligible to be used for federally-funded research. The bill authorizes HHS to support research involving embryonic stem cells meeting certain criteria, regardless of the date on which the stem cells were derived from an embryo.
- The bill lays out strict ethical guidelines, which allow federal funding for embryonic stem cell research. In order to acquire funding the following must be met:
- 1. Embryos used to develop stem cells must be originally created for fertility treatment and are in excess of treatment needs;

- 2. An embryo may only be used for stem cell research if the donors give their written consent.
- 3. The individuals seeking fertility treatments must have "donated the embryos with written informed consent and without receiving any financial or other inducements to make the donation."

###